Your ideal investment partner should mirror the traits you’d seek in any relationship. That’s why many investment banking pundits recommend seeking out specific qualities in an investor rather than simply the best terms for a specific transaction. The commitment, stability, connections, persistence and transparency of their investment partners are often cited as critical to the success of an issuer’s capital acquisition strategy.
Which explains why year after year, JMJ Financial continues to lead in small cap financing activity.
With investments in over 300 companies during our 15 years of operation, including over 70 new company investments last year alone, JMJ remains committed to the success of small cap growth companies and the economic benefit they bring to the US economy.
And over 1,100 investments in those firms demonstrate JMJ’s commitment to our portfolio companies, in both good times and bad. Do the math and you’ll see that our average portfolio company has received in excess of 3 tranches, fueling their continued growth and success.
JMJ has deep connections throughout the investment banking community, often working in concert with leading institutions to provide bridge funding as a part of a longer term fundraising and uplisting strategy.
Here are a few of our investment highlights:
ACTC: Advanced Cell Technology – JMJ investments totaled $8.5 million; the company uplisted to Nasdaq and was acquired for $400 million.
ADXS: Advaxis, Inc. – JMJ funding totaled $6.3 million, fueling an uplist to Nasdaq.
NWBO: Northwest Biotherapeutics, Inc. – $4.2 million invested from JMJ, an uplist to Nasdaq and has subsequently raised over $100 million.
MSLP: MusclePharm – JMJ’s $1.4 million investment powered revenue growth to over $120 million.
If your company or client is seeking investment from a solid, reputable partner or is thinking about an eventual uplist, please give us the opportunity to see how we can help.